



# Advanced Medical Solutions

Annual General Meeting

30 June 2025



Advanced Medical Solutions Group plc



## Highlights

### Strong growth and excellent progress integrating acquisitions



- **43% Group revenue growth** driven by strong Surgical performance and acquisitions
- **18% underlying revenue growth of Surgical business** (excluding Peters Surgical and Syntacoll)
- **Successful implementation of new US LiquiBand® route to market strategy** resulted in strong growth throughout 2024
- **Transformative acquisition of Peters Surgical in July 2024**, excellent progress made integrating business while adding £37.2 million to Group revenues
- **Syntacoll acquisition in March 2024** significantly strengthens Biosurgical expertise, capacity and growth potential
- LIQUIFIX™ already listed with two important US GPOs – **approval from largest and most significant GPO expected by end of March 2025**
- **Strategic initiatives for Woundcare Business Unit implemented in Q1** – expected to positively impact margins in 2025

## Transformative Acquisition: Peters Surgical



- **Acquisition of leading surgical business** closed on 1 July 2024 for an enterprise value of €132.5 million
- Significantly enhances our ability to **compete in the global suture category**
- **Expands direct selling capabilities** across key additional markets
- Development project started to **optimise IFABOND® portfolio for internal fixation**
- **Organisation integration of AMS and Peters Surgical teams completed – single Group wide teams** for all key functions
- **Dedicated integration team** supported by **external consultants** to deliver synergies relating to sutures



## Aquisition Progress: Syntacoll



- **Acquisition of market leading manufacturing facility** closed on 1 March 2024
- **Significantly enhances our collagen technical and manufacturing expertise and growth potential**
- **Contributed £5.6 million** to Group revenues in 2024
- **Revenues offset by incremental running costs, with Syntacoll breaking even** in 2024
- **Significant leverage of facility** anticipated in future years

## Summary and Outlook



- Strong financial performance in 2024
- New US LiquiBand® route to market strategy performing well and driving growth
- LIQUIFIX™ launched in the US with GPO approvals supporting accelerated growth
- **Transformative** acquisition of Peters Surgical
- Syntacoll acquisition strengthening Biosurgical business
- Integration of both businesses progressing well
- FY 2025 outlook unchanged, with revenue and EBITDA in line with the Board's expectations – 2025 has started well with good business performance
- The Group is well positioned for strong, long-term growth

## Contact



**Advanced Medical Solutions plc**  
**Premier Park, 33 Road One,**  
**Winsford Industrial Estate,**  
**Winsford, Cheshire**  
**W7 3RT, UK**

Chris Meredith (Chief Executive Officer)  
Eddie Johnson (Chief Financial Officer)  
Michael King (Investor Relations)

[corporate@admedsol.com](mailto:corporate@admedsol.com)  
**+44 (0)1606 863500**  
[www.admedsol.com](http://www.admedsol.com)